Daré Bioscience (DARE) investor relations material

Strategic focus and portfolio overview

• Emphasis on advancing women's health with a purpose-built portfolio targeting underserved markets, spanning contraception, menopause, sexual health, fertility, pregnancy management, and infectious disease.

• Two commercial products highlighted: Flora Sync LF5 (vaginal probiotic, launched June) and DARE to PLAY Sildenafil Cream (targeted for dispensing later this summer).

• Pipeline includes Ovaprene (non-hormonal contraceptive, phase III), DARE-HPV (HPV treatment, phase II), and DARE to RECLAIM (menopause, phase III enabling activities).

• Over $75 million in non-dilutive funding from Gates Foundation, ARPA-H, and NIH supports development from preclinical to late-stage programs.

• Digital-native commercialization model leverages provider relationships and the DARE Health Hub for seamless consumer and clinician engagement.

Commercialization and market opportunity

• Flora Sync LF5 is a non-prescription, clinically validated vaginal probiotic now available online, with strong clinical data showing rapid and sustained microbiome balance.

• DARE to PLAY Sildenafil Cream, formulated for women, is available for prescription as a 503B compounded product, with dispensing expected to begin soon.

• Provider relationships and digital platform enable cross-selling and rapid adoption, with both telehealth and in-office access.

• Commercial revenue generation began July 1, marking a transition from development to commercial stage.

• Early metrics and provider engagement indicate strong initial traction for both launches.

Development pipeline and clinical milestones

• Ovaprene phase III enrollment targeted for completion this year, with top-line data expected next year.

• DARE-HPV phase II trial underway, fully funded by ARPA-H, with top-line data anticipated next year.

• DARE to RECLAIM menopause hormone product aims for 2027 launch as a 503B compounded product.

• Additional pipeline includes non-hormonal menopause treatments and progesterone vaginal rings for fertility and pregnancy support, supported by NIH grants.

• Focus on first-in-category opportunities using known pharmaceutical ingredients in novel formulations.